OncLive.com @OncLive · 03 Sep 2026
Register now to attend the launch broadcast for JIDEYTRO™ (zidesamtinib), hosted by Dr. Mark Socinski, MD. Learn about trial data, efficacy outcomes, and safety profile of JIDEYTRO (zidesamtinib). Click here to sign-up: https://t.co/HDV2XI8Qku https://t.co/s4f8wWaORy
120Views
1Likes
0Reposts
0Replies
0Quotes
0Bookmarks
Is that a lot?
1.00×vs this author's median120 views is typical
40Percentile for this authorof 5 recent posts
0.04×vs 10K–100K median2 896 views is typical
0.24%Reachviews ÷ followers
0.83%Engagement rateof viewers reacted